{name}
{subtitle}
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~74 mi. (Tijuana, Mexico, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~87 mi. (Poway, California, +262 more cities)
facility
California Cancer Associates for Research & Excellence, Inc.
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
city
~89 mi. (San Diego, California, +523 more cities)
facility
Kaiser Permanente-San Diego Zion, +1 more facility
drug
cabozantinib, +2 more drugs
drug type
immunotherapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~89 mi. (San Diego, California, +454 more cities)
facility
Rady Children's Hospital - San Diego, +1 more facility
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~89 mi. (San Diego, California, +153 more cities)
facility
UC San Diego Medical Center - Hillcrest
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~89 mi. (San Diego, California, +825 more cities)
facility
Kaiser Permanente-San Diego Mission, +2 more facilities
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
city
~89 mi. (San Diego, California, +240 more cities)
facility
Kaiser Permanente-San Diego Zion
condition
Endometrial Adenocarcinoma, +5 more conditions
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type